Schrodinger Inc
Avatud
SektorTervishoid
18.75 -2.19
Ülevaade
Aktsiahinna muutus
24h
Min
18.75
Max
19.55
Sissetulek | 66M 6M |
|---|---|
Müük | 302K 59M |
Aktsiakasum | 0.08 |
Kasumimarginaal | 10.146 |
Töötajad | 850 |
EBITDA | 65M 7.3M |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | 361M 1.5B |
|---|---|
Eelmine avamishind | 20.94 |
Eelmine sulgemishind | 18.75 |
Uudiste sentiment
By Acuity
37%
63%
103 / 339 Pingereas Healthcare
Schrodinger Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Schrodinger Inc Prognoos
Sentiment
By Acuity
103 / 339 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.